IKENA ONCOLOGY INC. -

Ikena Oncology Reports Third Quarter 2024 Financial Results

07 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Reports Second Quarter 2024 Financial Results

08 авг 2024 15:15:00 Источник Nasdaq GlobeNewswire

UPDATE – Ikena Oncology Announces Strategic Update

28 май 2024 15:42:37 Источник Nasdaq GlobeNewswire

Ikena Oncology Announces Strategic Update

28 май 2024 15:15:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

13 май 2024 15:45:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

10 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

12 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

27 фев 2024 07:00:01 Источник Nasdaq GlobeNewswire

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

21 фев 2024 15:15:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

18 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

09 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

07 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Participate in September 2023 Investor Conferences

05 сен 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

10 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

07 авг 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Participate in Upcoming Investor Conferences

24 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

15 май 2023 06:50:00 Источник Nasdaq GlobeNewswire

Ikena Oncology Announces $40 Million Underwritten Offering

15 май 2023 06:45:00 Источник Nasdaq GlobeNewswire

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

20 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

17 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire